Learn how renal amyloidosis is diagnosed. From urine tests to kidney biopsies, understand the evaluation process and early detection methods at LivHospital.
Send us all your questions or requests, and our expert team will assist you.
The diagnostic journey typically begins when a patient presents with symptoms of nephrotic syndrome, such as unexplained swelling or foamy urine. The physician conducts a thorough physical examination, looking for signs of fluid overload, such as pitting edema in the legs or fluid in the lungs. They also look for specific clues that point toward amyloidosis rather than other kidney diseases.
Signs such as macroglossia (an enlarged tongue), periorbital purpura (bruising around the eyes, often called “raccoon eyes”), or easy bruising are highly suggestive of AL amyloidosis. These physical markers, while rare, are critical diagnostic clues that distinguish amyloidosis from standard diabetic nephropathy or hypertensive kidney disease.
The clinician reviews the patient’s medical history for chronic inflammatory conditions, which would point toward AA amyloidosis, or a family history of kidney or heart disease, suggesting a hereditary form. This initial detective work narrows the differential diagnosis and guides the subsequent testing strategy.
The first laboratory step is a comprehensive urinalysis. This simple test confirms the presence of protein in the urine. However, a standard dipstick primarily detects albumin. In some forms of amyloidosis, other proteins may be present, requiring a more detailed analysis.
A 24-hour urine collection is often ordered to quantify the exact amount of protein being lost. This helps stage the severity of the nephrotic syndrome. Alternatively, a spot urine protein-to-creatinine ratio can provide a reliable estimate. The presence of “free light chains” or Bence Jones proteins in the urine is a strong indicator of AL amyloidosis.
This blood test is the gold standard for screening for AL amyloidosis. It measures the levels of kappa and lambda light chains in the blood. In AL amyloidosis, the abnormal plasma cells produce an excess of one type, throwing off the normal ratio between the two.
An abnormal kappa/lambda ratio is highly suspicious for a plasma cell disorder. This test is extremely sensitive and helps differentiate AL amyloidosis from AA or hereditary forms, in which light-chain levels are typically normal. It is also used later to monitor response to treatment.
SPEP is a test that separates proteins in the blood based on their electrical charge. It helps identify a “M spike,” or monoclonal protein, indicating the presence of an abnormal clone of cells. This is followed by immunofixation electrophoresis (IFE) to identify the specific antibody type being produced.
While essential, SPEP is less sensitive than the free light chain assay for amyloidosis because the level of abnormal protein is often lower than in conditions like multiple myeloma. Therefore, both tests are usually performed together to ensure no diagnosis is missed.
A diagnosis of amyloidosis cannot be confirmed without a tissue biopsy. The least invasive method is a fat pad aspiration. A needle is inserted into the abdominal fat to withdraw cells. This tissue is then stained with a special dye called Congo Red.
When viewed under polarized light, amyloid deposits stained with Congo Red exhibit a characteristic “apple green birefringence.” This optical effect is the definitive proof of amyloid deposition. Fat pad biopsy is positive in about 70-80% of AL amyloidosis cases, but it is less sensitive in other types of amyloidosis.
If the fat pad biopsy is negative but suspicion remains high, a biopsy of the affected organ (the kidney) is performed. A renal biopsy provides direct evidence of amyloid deposition in the glomeruli and vessels. It allows the pathologist to assess the extent of the damage and scarring, providing prognostic information.
Confirming the presence of amyloid is only half the battle; determining the type is crucial because treatments differ vastly. Treating AL amyloidosis with anti-inflammatory drugs (for AA) or vice versa can be fatal.
Typing is performed by immunohistochemistry, in which antibodies against specific amyloid proteins are applied to the biopsy sample. However, the gold standard for typing is laser microdissection and mass spectrometry. This advanced technique uses a laser to remove amyloid deposits and analyzes their exact protein composition with nearly 100 percent accuracy.
SAP (Serum Amyloid P) scintigraphy is a specialized nuclear medicine scan available in select specialist centers. It involves injecting radio-labeled SAP, which binds to amyloid deposits throughout the body. This creates a “whole body map” of the disease, revealing the extent of organ involvement in the liver, spleen, kidneys, and bones.
Cardiac MRI with late gadolinium enhancement is crucial for evaluating heart involvement. Since cardiac amyloidosis determines survival, this imaging helps risk-stratify the patient. It can detect amyloid deposits in the heart muscle before symptoms of heart failure appear.
If AL and AA amyloidosis are ruled out, or if the family history suggests it, genetic testing is mandatory. This involves sequencing the genes known to cause hereditary amyloidosis, such as fibrinogen, apolipoprotein, and lysozyme.
Identifying a genetic mutation significantly changes the management plan. It may imply that liver transplantation is a curative option (to stop the production of the mutant protein) and alerts family members to the need for screening.
Once the diagnosis is confirmed, the functional status of the kidneys and other organs must be staged. This involves calculating the eGFR to determine the stage of kidney disease. Cardiac biomarkers such as NT-proBNP and Troponin are measured to assess cardiac stress.
These functional markers are used to stage the disease (Stages I-IV for AL amyloidosis). The stage dictates the eligibility for aggressive treatments like stem cell transplant versus milder chemotherapy regimens.
Send us all your questions or requests, and our expert team will assist you.
If you are diagnosed with AL amyloidosis, a bone marrow biopsy is necessary to look at the plasma cells that are producing the amyloid. It helps doctors determine the percentage of marrow involved and assess specific genetic abnormalities in cells that guide chemotherapy choices.
No. A fat pad biopsy is a great screening test because it is easy and painless, but it misses about 20 to 30 percent of cases. If the fat pad is negative but your doctor still suspects amyloidosis, they will need to biopsy the kidney or another affected organ to be sure.
It is done with local anesthesia to numb the skin and muscle. You might feel pressure, but sharp pain is rare. You will have to lie flat on your back for several hours afterward to prevent bleeding, which can be uncomfortable, but the procedure itself is generally well tolerated.
Typing means figuring out exactly which protein is forming the deposits. This is the most critical step. AL type is treated with chemo; AA type is treated by fighting inflammation; Hereditary type might need a liver transplant. Guessing the kind based on symptoms alone is dangerous.
It can be a long process because the disease is rare. From the first symptoms to a final diagnosis often takes several months and multiple specialists. However, once a biopsy is done, the pathology results and typing usually take 1 to 2 weeks.
Your Comparison List (you must select at least 2 packages)
